United States

People: Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

20 Jan 2017
Change (% chg)

$-0.04 (-0.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sherman, Matthew 

Dr. Matthew L. Sherman, M.D., is Executive Vice President and Chief Medical Officer of the Company. He joined Acceleron in May 2006. Previously, he served as Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals Corp. where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs, quality assurance and program management. Prior to that, Dr. Sherman worked at Genetics Institute and Wyeth Pharmaceuticals in various capacities including Therapeutic Area Director for Oncology. While at Wyeth, Dr. Sherman provided senior oncology and hematology leadership for worldwide clinical development for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg® by the FDA. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Sherman received an SB in chemistry from the Massachusetts Institute of Technology and an MD from Dartmouth Medical School.

Basic Compensation

Total Annual Compensation, USD 413,033
Restricted Stock Awards, USD 1,430,140
Long-Term Incentive Plans, USD --
All Other, USD 1,573,990
Fiscal Year Total, USD 3,417,170

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Francois Nader


Habib Dable


Kevin McLaughlin


Steven Ertel


Matthew Sherman


Ravindra Kumar

As Of  30 Dec 2015